Literature DB >> 28871554

The Impact of Histologic Phenotype in the Treatment of Sinonasal Cancer.

Fernando López1,2, Valerie J Lund3, Carlos Suárez4, Carl H Snyderman5, Nabil F Saba6, K Thomas Robbins7, Vincent Vander Poorten8, Primož Strojan9, William M Mendenhall10, Alessandra Rinaldo11, Alfio Ferlito12.   

Abstract

The management of sinonasal cancer is a challenge due to its low occurrence and anatomical and significant diversity of histological types. The therapeutic modality used should be tailored individually according to the histology, tumour stage, molecular profile and previous treatments. The clinical management of sinonasal cancer has improved greatly owing to developments in endoscopic surgery and precision radiotherapy. Complete surgical resection is the mainstay of sinonasal malignancies' management but multimodality therapy is associated with improved outcomes in certain histologies. The recognition of various histological types with biological behaviours more suitable for non-surgical modalities has allowed treatment protocols to become more tailored to the disease. In this review we aim to describe and to summarise the current data guiding the management of sinonasal cancer with emphasis on phenotypic variation.

Entities:  

Keywords:  Endoscopic surgery; Histology; Oncology; Paranasal cavities; Radiotherapy; Sinonasal cancer

Mesh:

Year:  2017        PMID: 28871554     DOI: 10.1007/s12325-017-0605-9

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  7 in total

1.  Does Reorganization of Clinicopathological Information Improve Prognostic Stratification and Prediction of Chemoradiosensitivity in Sinonasal Carcinomas? A Retrospective Study on 145 Patients.

Authors:  Marco Ferrari; Davide Mattavelli; Alberto Schreiber; Tommaso Gualtieri; Vittorio Rampinelli; Michele Tomasoni; Stefano Taboni; Laura Ardighieri; Simonetta Battocchio; Anna Bozzola; Marco Ravanelli; Roberto Maroldi; Cesare Piazza; Paolo Bossi; Alberto Deganello; Piero Nicolai
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

Review 2.  The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours.

Authors:  Fernando López; Jatin P Shah; Jonathan J Beitler; Carl H Snyderman; Valerie Lund; Cesare Piazza; Antti A Mäkitie; Orlando Guntinas-Lichius; Juan P Rodrigo; Luiz P Kowalski; Miquel Quer; Ashok Shaha; Akihiro Homma; Alvaro Sanabria; Renata Ferrarotto; Anne W M Lee; Victor H F Lee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2022-03-30       Impact factor: 4.070

Review 3.  Novel Biomarkers in Sinonasal Cancers: from Bench to Bedside.

Authors:  Matt Lechner; Jacklyn Liu; Valerie J Lund
Journal:  Curr Oncol Rep       Date:  2020-07-29       Impact factor: 5.075

4.  Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma.

Authors:  Huatao Quan; Li Yan; Shuyi Wang; Shengzi Wang
Journal:  Cancer Manag Res       Date:  2019-05-09       Impact factor: 3.989

5.  Navigation-Guided Transnasal Endoscopic Delineation of the Posterior Margin for Maxillary Sinus Cancers: A Preclinical Study.

Authors:  Stefano Taboni; Marco Ferrari; Michael J Daly; Harley H L Chan; Donovan Eu; Tommaso Gualtieri; Ashok R Jethwa; Axel Sahovaler; Andrew Sewell; Wael Hasan; Ilyes Berania; Jimmy Qiu; John de Almeida; Piero Nicolai; Ralph W Gilbert; Jonathan C Irish
Journal:  Front Oncol       Date:  2021-11-11       Impact factor: 6.244

6.  Radiooncological View on Therapy Outcome after Multidisciplinary Treatment of Sinonasal Tumors.

Authors:  Olena Klymenko; Anna Maria Stefanie Buchberger; Barbara Wollenberg; Klaus-Dietrich Wolff; Victoria Kehl; Stephanie E Combs; Anja Pickhard; Steffi U Pigorsch
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 7.  Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment.

Authors:  Mario Turri-Zanoni; Giacomo Gravante; Paolo Castelnuovo
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.